Blueprint Medicines Corp. started an underwritten public offering of common shares to raise $325 million.
The Cambridge, Mass.-based biotech company expects to grant underwriters an option to purchase up to an additional $48.8 million worth of shares.
Blueprint plans to use the proceeds from the offering to finance regulatory filings and commercial activities for Ayvakit, or avapritinib, and pralsetinib, which is still pending regulatory review.
The U.S. Food and Drug Administration approved Ayvakit in January to treat certain gastrointestinal tumors that can not be surgically removed or have spread to other parts of the body.
Funds from the offering will also be used for the clinical development of Ayvakit and pralsetinib in other indications as well as other experimental treatments. The amount raised in the offering will cover manufacturing costs for Ayvakit, working capital requirements and other general corporate purposes, Blueprint noted in a Jan. 21 press release.
Goldman Sachs & Co. LLC and Cowen and Co. LLC are joint book-running managers for the offering, while Canaccord Genuity LLC, JMP Securities LLC and Raymond James & Associates Inc. are co-lead managers.